Cybersecurity Incident at Synnovis in UK
EQS-News: SYNLAB AG / Key word(s): Statement
Cybersecurity Incident at Synnovis in UK
04.06.2024 / 20:46 CET/CEST
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Cybersecurity Incident at Synnovis in UK
SYNLAB AG ('SYNLAB', FSE: SYAB) confirms that Synnovis, a partnership
between two London-based hospital Trusts and SYNLAB UK & Ireland, was the
victim of a cyber-attack on 3 June 2024.
A taskforce of IT experts from Synnovis and the National Health Service in
UK (NHS England) is working diligently to fully assess the impact the attack
has had, and to take the appropriate action needed. Synnovis is working
closely with NHS Trust partners to minimise the impact on patients and other
service users.
It is an isolated incident to Synnovis with no connection to the
cyber-attack on SYNLAB Italy on 18 April 2024. The rest of the SYNLAB Group
including the other SYNLAB facilities in the UK are not impacted.
Regrettably this is affecting patients, with some activity already cancelled
or redirected to other providers as urgent work is prioritised. Synnovis is
working under high pressure to minimise the impact and update patients and
partners on further developments.
SYNLAB and Synnovis apologize for the impact resulting from this criminal
attack.
- Ends -
For more information:
Media contact: +49 (0) 151 466 938 56
Diana Tabor, FTI Consulting (1)media-contact@synlab.com
1. mailto:media-contact@synlab.com
Investor contact: +49 (0) 151 6701 3130
Etienne Ziller, SYNLAB (1)ir@synlab.com
1. mailto:ir@synlab.com
About SYNLAB
* SYNLAB Group is the leader in medical diagnostic services and specialty
testing in Europe. The Group offers a full range of innovative and
reliable medical diagnostics to patients, practising doctors, hospitals
and clinics, governments and corporates.
* Providing the leading level of service within the industry, SYNLAB is
the partner of choice for routine and specialty diagnostics in human
medicine. The Group continuously innovates medical diagnostic services
for the benefit of patients and customers.
* SYNLAB operates in more than 30 countries across four continents and
holds leading positions in most markets, regularly reinforcing the
strength of its network through a proven acquisition strategy. More than
27,000 employees, including over 2,000 medical experts, contribute every
day to the Group's worldwide success.
* SYNLAB performed around 600 million laboratory tests and achieved
revenues of EUR2.64 billion in 2023.
* Ticker symbol: SYAB; ISIN: DE000A2TSL71
* More information can be found on www.synlab.com
SYNLAB - forward looking statements
This document does not constitute or form a part of, and should not be
construed as, an offer for sale or subscription of or solicitation of any
offer to purchase or subscribe for any securities in any jurisdiction.
Statements made in this document may include forward-looking statements.
Forward-looking statements include all statements that are not historical
facts and can be identified by the use of forward-looking terminology such
as the words 'believes', 'expects', 'expected', 'may', 'will', 'would',
'should', 'seeks', 'pro forma', 'anticipates', 'intends', 'plans',
'estimates', 'estimated', or the negative of any thereof or other variations
thereof or comparable terminology, or by discussions of strategy or
intentions. These statements are not guarantees of future actions or
performance and involve risks, uncertainties and assumptions as to future
events that may not prove to be accurate. Actual actions or results may
differ materially from what is expressed or forecasted in these
forward-looking statements. As a result, these statements speak only as of
the date they were made and SYNLAB undertakes no obligation to publicly
update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise. It should be noted that past
performance is not a guide to future performance. Interim results are not
necessarily indicative of full-year results.
---------------------------------------------------------------------------
04.06.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com
---------------------------------------------------------------------------
Language: English
Company: SYNLAB AG
Moosacher Straße 88
80809 Munich
Germany
Phone: +49 1701183753
E-mail: ir@synlab.com
Internet: www.synlab.com/
ISIN: DE000A2TSL71
WKN: A2TSL7
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard);
Regulated Unofficial Market in Berlin, Dusseldorf,
Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1918021
End of News EQS News Service
---------------------------------------------------------------------------
1918021 04.06.2024 CET/CEST